

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person * <u>Fletcher Aaron G.L.</u> (Last) (First) (Middle) C/O LANTERN PHARMA INC. 1920 MCKINNEY AVENUE, 7TH FLOOR (Street) DALLAS TX 75201 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Lantern Pharma Inc. [LTRN]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 11/08/2022	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/08/2022		S		58,711	D	\$4.4	271,193	I	By Bios Fund I QP, LP ⁽¹⁾⁽²⁾⁽³⁾
Common Stock	11/08/2022		S		100,380	D	\$4.4	463,658	I	By Bios Fund I, LP ⁽¹⁾⁽²⁾⁽³⁾
Common Stock	11/08/2022		S		17,748	D	\$4.4	71,774	I	By Bios Fund II NT, LP ⁽¹⁾⁽²⁾⁽³⁾
Common Stock	11/08/2022		S		132,575	D	\$4.4	536,163	I	By Bios Fund II QP, LP ⁽¹⁾⁽²⁾⁽³⁾
Common Stock	11/08/2022		S		40,586	D	\$4.4	164,137	I	By Bios Fund II, LP ⁽¹⁾⁽²⁾⁽³⁾
Common Stock								26,093	I	By BP Directors, LP ⁽¹⁾⁽²⁾⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person * <u>Fletcher Aaron G.L.</u> (Last) (First) (Middle) C/O LANTERN PHARMA INC. 1920 MCKINNEY AVENUE, 7TH FLOOR (Street) DALLAS TX 75201 (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person *

[BIOS Fund I, LP](#)

(Last) (First) (Middle)

1401 FOCH STREET
SUITE 140

(Street)

FORT WORTH TX 76107

(City) (State) (Zip)

1. Name and Address of Reporting Person *

[BIOS Fund I QP, LP](#)

(Last) (First) (Middle)

1401 FOCH STREET, SUITE 140

(Street)

FORT WORTH TX 76107

(City) (State) (Zip)

1. Name and Address of Reporting Person *

[BIOS Fund II, LP](#)

(Last) (First) (Middle)

1401 FOCH STREET
SUITE 140

(Street)

FORT WORTH TX 76107

(City) (State) (Zip)

1. Name and Address of Reporting Person *

[BIOS Fund II QP, LP](#)

(Last) (First) (Middle)

1401 FOCH STREET
SUITE 140

(Street)

FORT WORTH TX 76107

(City) (State) (Zip)

1. Name and Address of Reporting Person *

[BIOS Fund II NT, LP](#)

(Last) (First) (Middle)

1401 FOCH STREET, SUITE 140

(Street)

FORT WORTH TX 76107

(City) (State) (Zip)

1. Name and Address of Reporting Person *

[Bios Equity Partners, LP](#)

(Last) (First) (Middle)

1751 RIVER RUN, SUITE 400

(Street)

FORT WORTH TX 76107

(City) (State) (Zip)

1. Name and Address of Reporting Person *		
Bios Equity Partners II, LP		
(Last)	(First)	(Middle)
1751 RIVER RUN, SUITE 400		
(Street)		
FORT WORTH	TX	76107
(City)	(State)	(Zip)
1. Name and Address of Reporting Person *		
BIOS Capital Management, LP		
(Last)	(First)	(Middle)
1751 RIVER RUN SUITE 400		
(Street)		
FORT WORTH	TX	76107
(City)	(State)	(Zip)
1. Name and Address of Reporting Person *		
BIOS Advisors GP, LLC		
(Last)	(First)	(Middle)
1751 RIVER RUN SUITE 400		
(Street)		
FORT WORTH	TX	76107
(City)	(State)	(Zip)

Explanation of Responses:

- Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
- Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. Bios
- For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks:

This Form 4 is the second of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The first Form 4 was filed by Leslie W. Kreis, Jr. as the designated filer.

[/s/ Aaron G.L. Fletcher](#) [11/09/2022](#)

[Bios Fund I, LP By: Bios Equity Partners, LP, its general partner](#)
[By: Bios Capital Management, LP, its general partner](#) [By: Bios Advisors GP, LLC, its general partner](#) [By: /s/ Aaron Glenn Louis Fletcher, Manager](#)

[11/09/2022](#)

[Bios Fund I QP, LP By: Bios Equity Partners, LP, its general partner](#)
[By: Bios Capital Management, LP, its general partner](#) [By: Bios Advisors GP, LLC, its general partner](#) [By: /s/ Aaron Glenn Louis Fletcher, Manager](#)

[11/09/2022](#)

[Bios Fund II, LP By: Bios Equity Partners II, LP, its general partner](#)
[By: Bios Capital Management, LP, its general partner](#) [By: Bios Advisors GP, LLC, its general partner](#) [By: /s/ Aaron Glenn Louis Fletcher, Manager](#)

[11/09/2022](#)

Bios Fund II OP, LP By: Bios
Equity Partners II, LP, its general
partner By: Bios Capital
Management, LP, its general
partner By: Bios Advisors GP,
LLC, its general partner By: /s/
Aaron Glenn Louis Fletcher,
Manager 11/09/2022

Bios Fund II NT, LP By: Bios
Equity Partners II, LP, its general
partner By: Bios Capital
Management, LP, its general
partner By: Bios Advisors GP,
LLC, its general partner By: /s/
Aaron Glenn Louis Fletcher,
Manager 11/09/2022

Bios Equity Partners, LP By: Bios
Capital Management, LP, its
general partner By: Bios Advisors
GP, LLC, its general partner By:
/s/ Aaron Glenn Louis Fletcher,
Manager 11/09/2022

Bios Equity Partners II, LP By:
Bios Capital Management, LP, its
general partner By: Bios Advisors
GP, LLC, its general partner By:
/s/ Aaron Glenn Louis Fletcher,
Manager 11/09/2022

Bios Capital Management, LP By:
Bios Advisors GP, LLC, its
general partner By: /s/ Aaron
Glenn Louis Fletcher, Manager 11/09/2022

Bios Advisors GP, LLC By: /s/
Aaron Glenn Louis Fletcher,
Manager 11/09/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.